Metagenomi, Inc.
MGX
$1.67
$0.159.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.84% | 45.13% | 83.36% | 109.93% | 160.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.84% | 45.13% | 83.36% | 109.93% | 160.21% |
| Cost of Revenue | 15.65% | 30.77% | 61.16% | 92.76% | 118.83% |
| Gross Profit | -14.58% | -19.12% | -43.61% | -80.80% | -91.40% |
| SG&A Expenses | 11.00% | 20.05% | 38.05% | 46.51% | 54.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.56% | 28.16% | 55.21% | 79.84% | 99.30% |
| Operating Income | -13.26% | -19.46% | -41.48% | -67.20% | -75.83% |
| Income Before Tax | -38.76% | -31.50% | -50.83% | -54.59% | -46.81% |
| Income Tax Expenses | -168.68% | -125.69% | -68.90% | 38.15% | 212.46% |
| Earnings from Continuing Operations | -14.36% | -16.30% | -38.51% | -53.21% | -56.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.36% | -16.30% | -38.51% | -53.21% | -56.57% |
| EBIT | -13.26% | -19.46% | -41.48% | -67.20% | -75.83% |
| EBITDA | -12.40% | -18.47% | -40.46% | -65.70% | -73.13% |
| EPS Basic | 85.24% | 53.26% | 4.78% | -4.05% | -69.37% |
| Normalized Basic EPS | 84.30% | 54.63% | 6.16% | -5.42% | -62.64% |
| EPS Diluted | 85.24% | 53.26% | 4.78% | -4.05% | -69.37% |
| Normalized Diluted EPS | 84.30% | 54.63% | 6.16% | -5.42% | -62.64% |
| Average Basic Shares Outstanding | 604.84% | 423.59% | 245.35% | 125.81% | 0.23% |
| Average Diluted Shares Outstanding | 604.84% | 423.59% | 245.35% | 125.81% | 0.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |